medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  

Clinical  validity  of  expanded  carrier  screening:  evaluating  the  gene-­disease  
relationship  in  more  than  200  conditions  
  
Marie  Balzotti,1  Linyan  Meng,2  Dale  Muzzey,1  Katherine  Johansen  Taber,1  Kyle  Beauchamp,1,3  
Myriad  Genetics  Curation  Team,1  Baylor  Genetics  Curation  Team,2  Rebecca  Mar-­Heyming,1,4  
Bethany  Buckley,1,5  Krista  Moyer1    
  
Myriad  Genetics  Curation  Team  
David  Tran,  Jessica  Conner,  Megan  Li,  Martha  Arnaud,  Lynne  Nazareth,  Kerri  Hensley,  Michael  
Hunter,  Sam  Cox,  Domenic  Previte,  Brianna  Campbell,  Katrina  Tanaka,  Candy  Heyen,  Kaitlin  
Sesock,  Srikanth  Appikonda,  Ildiko  Thibodeau,  Majesta  O'Bleness,  Matthew  Brown,  Caiqian  
Cropper,  Brandee  Price,  Juliette  Kahle,  Kamalika  Moulick,  Jessica  Ray,  John  Castiblanco,  Lea  
Gemmel,  Lisa  Spock,  Megan  Judkins  
  
Baylor  Genetics  Curation  Team  
Blake  Atwood,  Shen  Gu,  Ye  Cao,  Rajarshi  Ghosh,  Bo  Yuan,  Fan  Xia  
  
1.  Myriad  Genetics,  South  San  Francisco,  CA  
2.  Baylor  Genetics,  Houston,  TX  
3.  Current  affiliation:  Tempus,  Redwood  City,  CA  
4.  Current  affiliation:  Ambry  Genetics,  Aliso  Viejo,  CA  
5.  Current  affiliation:  Invitae,  San  Francisco,  CA  
  
Author  for  correspondence:  Krista  Moyer,  mwh-­research@myriad.com  
  
Author  ORCiD  IDs:    
Kyle  Beauchamp:  0000-­0001-­6095-­8788    
Katie  Johansen  Taber:  0000-­0003-­3051-­2667      
Krista  Moyer:  0000-­0003-­3857-­9372  
Dale  Muzzey:  0000-­0001-­8822-­2035    

  
1  

  

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  

Abstract  
Objective:  
Clinical  guidelines  consider  expanded  carrier  screening  (ECS)  to  be  an  acceptable  method  of  
carrier  screening.  However,  broader  guideline  support  and  payer  adoption  require  evidence  for  
associations  between  the  genes  on  ECS  panels  and  the  conditions  for  which  they  aim  to  identify  
carriers.  We  applied  a  standardized  framework  for  evaluation  of  gene-­disease  association  to  
assess  the  clinical  validity  of  conditions  screened  by  ECS  panels.      
  
Methods:  
The  ClinGen  gene  curation  framework  was  used  to  assess  genetic  and  experimental  evidence  
of  associations  between  208  genes  and  conditions  screened  on  two  commercial  ECS  panels.  
Twenty-­one  conditions  were  previously  classified  by  ClinGen,  and  the  remaining  187  were  
evaluated  by  curation  teams  at  two  laboratories.  To  ensure  consistent  application  of  the  
framework  across  the  laboratories,  concordance  was  evaluated  on  a  subset  of  conditions.  
  
Results:  
All  208  evaluated  conditions  met  the  evidence  threshold  for  supporting  a  gene-­disease  
association.  Furthermore,  203  of  208  (98%)  achieved  the  strongest  (“Definitive”)  level  of  gene-­
disease  association.  All  conditions  evaluated  by  both  commercial  laboratories  were  similarly  
classified.    
  
Conclusion:  
Assessment  using  the  ClinGen  standardized  framework  revealed  strong  evidence  of  gene-­
disease  association  for  conditions  on  two  ECS  panels.  This  result  establishes  the  disease-­level  
clinical  validity  of  the  panels  considered  herein.      
2  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  

Introduction  
A  genetic  test  has  clinical  validity  if  it  accurately  detects  genetic  variations  associated  with  
clinical  outcomes  of  interest.  For  screening  panels  comprised  of  tens  to  hundreds  of  single-­gene  
disorders,  clinical  validity  is  demonstrated,  in  part,  by  evidence  of  association  between  each  
gene  and  its  ostensibly  associated  condition.  Clinicians  offering  testing  to  their  patients  must  
have  confidence  that  the  role  of  a  gene  in  disease  causation  is  well  established  so  that  accurate  
diagnoses  can  be  made  and  appropriate  management  undertaken  based  on  the  test  result.  
Evidence  demonstrating  clinical  validity  is  often  a  foundational  requirement  for  clinical  guidelines  
to  support  genetic  testing  (Grody  et  al.,  2013;;  National  Academies  of  Sciences  Engineering  and  
Medicine,  2017).  Similarly,  insurers  cite  the  lack  of  clinical  validity  evidence  as  a  reason  for  non-­
coverage  of  some  genetic  tests  (Chambers  et  al.,  2017).    
  
The  purpose  of  carrier  screening  is  to  determine  whether  couples  are  at  high  risk  of  having  
children  affected  with  serious  genetic  conditions,  allowing  for  informed  reproductive  decision-­
making  and  pregnancy  management.  The  number  of  gene-­disease  pairs  currently  available  for  
carrier  screening  varies  across  laboratories,  with  some  offering  screening  for  only  a  few  
conditions  and  others  offering  screening  for  hundreds  (termed  expanded  carrier  screening  or  
ECS).  Many  factors  influence  the  selection  of  conditions  that  are  included  on  ECS  panels,  such  
as  the  severity  of  the  condition  and  its  prevalence  in  the  population,  as  well  as  the  screen’s  
clinical  sensitivity  for  pathogenic  variants  (Beauchamp  et  al.,  2018;;  Ben-­Shachar  et  al.,  2019;;  
Kaseniit  et  al.,  2019).  Regardless  of  the  differences  in  the  sets  of  conditions  screened  by  
commercial  ECS  panels,  all  conditions  on  a  given  panel  should  have  established  clinical  validity  
at  the  level  of  gene-­disease  association  because  important  reproductive  and  pregnancy  
management  decisions  are  made  based  on  results.  However,  to  our  knowledge,  no  systematic  
evaluations  of  gene-­disease  associations  on  ECS  panels  have  been  undertaken.    
3  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
  
The  Clinical  Genome  Resource  (ClinGen)  (Rehm  et  al.,  2015)  has  developed  a  framework  to  
classify  gene-­disease  relationships  by  the  quantity  and  quality  of  the  evidence  supporting  such  
a  relationship  (Strande  et  al.,  2017).  The  framework  provides  a  system  by  which  supporting  and  
contradictory  gene-­disease  association  evidence  can  be  organized  and  then  categorized  by  
strength,  resulting  in  a  quantification  of  clinical  validity  for  the  gene-­disease  relationship  being  
interrogated.  Evidence  classifications  that  are  supportive  of  an  association  include  “Definitive,”  
“Strong,”  “Moderate,”  and  “Limited.”  Contradictory  classifications  include  “Disputed”  and  
“Refuted.”  A  classification  of  “No  reported  evidence”  indicates  no  reported  pathogenic  or  likely  
pathogenic  variants  in  humans.  
  
The  ClinGen  gene-­disease  association  framework  has  been  applied  in  a  number  of  disease-­
specific  areas  to  determine  the  clinical  validity  of  genes  included  on  panels  (DiStefano  et  al.,  
2019;;  Hosseini  et  al.,  2018;;  Ingles  et  al.,  2019;;  Lee  et  al.,  2019;;  McGlaughon  et  al.,  2019;;  
Renard  et  al.,  2018;;  Seifert  et  al.,  2019).  For  example,  of  21  genes  included  on  panels  
assessing  single-­gene  causes  of  Brugada  syndrome,  an  arrhythmia  condition  that  increases  risk  
for  sudden  cardiac  death,  only  one  gene  (SCN5A)  was  classified  as  having  Definitive  evidence  
of  clinical  validity,  while  the  remaining  20  were  classified  as  Disputed  (Hosseini  et  al.,  2018).  
The  study  concluded  that  more  evidence  was  needed  before  genes  other  than  SCN5A  are  
tested  as  the  cause  of  Brugada  syndrome  (Hosseini  et  al.,  2018).  Another  study  applied  the  
framework  to  31  genes  associated  with  hereditary  cancer  syndromes  (Lee  et  al.,  2019).  The  
study  classified  the  evidence  as  supportive  for  25  genes  (Definitive  for  18,  Moderate  for  1,  and  
Limited  for  6),  and  as  contradictory  (Disputed)  for  three  genes;;  it  found  no  reported  evidence  for  
two  genes.  The  authors  suggested  that  their  results  could  be  used  to  optimize  the  design  of  
hereditary  cancer  panels  (Lee  et  al.,  2019).    
  
4  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
In  this  study,  we  have  used  the  ClinGen  framework  to  assess  the  clinical  validity  of  the  gene-­
disease  relationship  for  more  than  200  autosomal  recessive  and  X-­linked  conditions  included  on  
commercially  available  ECS  panels.    
  

Methods  
Editorial  Policies  and  Ethical  Considerations  
This  study  did  not  involve  human  participants  and  therefore  was  not  subject  to  ethical  review  or  
institutional  review  board  approval.  
  
Gene  Curation  Framework  
The  ClinGen  gene  curation  framework  provides  a  method  to  evaluate  the  strength  of  a  gene-­
disease  association  (Strande  et  al.,  2017).  According  to  this  framework,  papers  published  in  
peer-­reviewed  journals  are  curated  for  different  evidence  types,  specifically  genetic  and  
experimental  evidence.  Genetic  evidence  includes  case-­level  data  (e.g.,  studies  describing  
individuals  with  variants  in  the  gene  of  interest  and  segregation  analysis)  and  case-­control  data.  
Experimental  evidence  is  grouped  into  three  main  categories:  functional  evidence  (e.g.,  
biochemical,  protein  interactions,  expression),  functional  alteration  evidence  (e.g.,  the  gene  or  
gene  product  function  is  altered  in  patient  or  non-­patient  cells  with  candidate  mutations),  and  
models/rescue  evidence  (e.g.,  replication  of  the  disease  in  a  model  organism  or  model  system,  
and  rescue  of  the  disease  phenotype  with  wild-­type  gene  or  gene  product).  Curated  genetic  and  
experimental  evidence  from  the  literature  is  gathered  and  assigned  points;;  higher  point  values  
reflect  stronger  support  for  the  association  (see  Gene  Curation  below).  For  example,  
model/rescue  experiments  are  assigned  higher  default  points  (1-­2  points)  than  function  
experiments  (0.5  points).  The  maximum  number  of  points  obtainable  for  genetic  and  

5  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
experimental  evidence  is  12  and  6  points,  respectively.  Following  data  collection,  annotation  
and  summing  the  evidence  points,  one  of  seven  possible  clinical  validity  classifications  is  
assigned  to  each  gene-­disease  pair.  Supportive  classifications  are  based  on  the  total  point  sum  
and  qualify  the  level  of  support  for  the  association:  “Definitive”  (12-­18  points  plus  replication  
over  time,  i.e.,  three  or  more  independent  publications  with  convincing  evidence  over  a  time  
frame  greater  than  three  years),  “Strong”  (12-­18  points  without  replication  over  time),  
“Moderate”  (7-­11  points),  and  “Limited”  (1-­6  points).  Further,  a  classification  of  “No  Reported  
Evidence”  is  applied  to  gene-­disease  pairs  for  which  there  are  no  reports  of  patients  with  the  
disease  having  pathogenic  or  likely  pathogenic  variants  in  the  gene.  Two  classifications  exist  
within  the  framework  for  gene-­disease  associations  with  contradictory  evidence:  “Disputed”  is  
applied  when  valid  contradictory  evidence  has  arisen  since  the  initial  gene-­disease  association  
claim,  and  “Refuted”  is  applied  when  the  gene-­disease  association  has  been  fully  refuted  by  
valid  contradictory  evidence  since  the  time  of  the  original  claim.    
  
Gene  Curation  
The  ClinGen  framework  was  applied  to  208  gene-­disease  pairs  included  in  commercially  
available  ECS  panels  by  Myriad  Women’s  Health  (Foresight)  and  Baylor  Genetics  
(GeneAware).  The  208  gene-­disease  pairs  were  curated  independently  at  Myriad  and/or  Baylor  
as  described  below  and  as  listed  in  Supplementary  Table  1.  Each  gene  curation  team  consisted  
of  gene  curators  and  a  laboratory  director.  Gene  curators  (who  are  specially  trained  scientists  
with  Masters  and/or  PhD  degrees)  followed  the  ClinGen  Gene  Curation  Standard  Operation  
Procedure,  Version  5  (The  Clinical  Genome  Resource  Gene  Curation  Working  Group,  2017).  
Curation  could  be  discontinued  once  a  “Definitive”  classification  was  reached:  i.e.,  once  ≥12  
points  of  genetic  evidence  had  been  amassed  and  at  least  two  pieces  of  experimental  evidence  
had  been  curated  from  two  or  more  independent  papers  (non-­overlapping  clinical  studies  
produced  by  different  groups).  Each  gene-­disease  pair  was  curated  by  a  single  curator,  and  
6  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
then  laboratory  directors  reviewed  all  gene  curations  for  appropriate  application  of  the  
framework  and  point  assignments;;  evaluated  contradictory  evidence,  if  any;;  assessed  
consistency;;  recommended  changes  when  needed;;  and  approved  gene  curations  that  met  
review  criteria.  A  set  of  21  gene-­disease  pairs  were  curated  independently  by  both  Myriad  and  
Baylor  to  determine  the  level  of  classification  concordance  between  the  two  institutions.  These  
gene-­disease  pairs  were  chosen  to  represent  both  average  difficulty  curations  (those  with  clear  
case  and  experimental  data  or  clear  mechanism  of  action,  for  example)  and  challenging  
curations  (those  with  few  cases  or  experimental  studies,  for  example).  Gene-­disease  pairs  with  
conflicting  classifications  between  the  two  institutions  were  examined,  evidence  was  combined  
where  applicable,  and  the  appropriate  assignment  of  points  was  discussed  between  Myriad  and  
Baylor  laboratory  directors  until  a  concordant  classification  was  reached.  ClinGen  gene  curation  
expert  panels  had  previously  curated  and  assigned  clinical  validity  classifications  to  an  
additional  21  gene-­disease  pairs  that  were  included  in  the  ECS  panels  evaluated  in  this  study  
(DiStefano  et  al.,  2019;;  McGlaughon  et  al.,  2019;;  The  Clinical  Genome  Resource);;  we  did  not  
reapply  the  framework  to  these  21  genes  (Supplementary  Table  1).  In  addition  to  the  208  
conditions  included  on  Myriad’s  and  Baylor’s  ECS  panels,  Myriad  also  evaluated  nine  recessive  
conditions  not  typically  screened  during  expanded  carrier  screening  (Supplementary  Table  2).  
All  classifications  have  been  submitted  to  ClinGen  for  public  availability.  
  

Results  
The  gene-­disease  relationship  of  each  of  208  conditions  included  on  two  commercially  available  
ECS  panels  was  evaluated  using  the  ClinGen  framework.  In  total,  more  than  2,000  pieces  of  
evidence  were  included  in  the  final  classifications,  with  each  gene-­disease  pair  having  a  median  
of  11  pieces  of  evidence  (Figure  1).  Of  the  208  conditions,  203  (98%)  were  found  to  have  a  

7  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
Definitive  association,  the  strongest  level  of  evidence  for  clinical  validity  (Figure  1,  Table  1,  
Supplementary  Table  1).  Of  the  remaining  five  conditions,  four  were  classified  as  having  
Moderate  evidence  and  one  was  classified  as  having  Limited  evidence  (Figure  1,  Table  1,  
Supplementary  Table  1).  Notably,  all  evaluated  conditions  were  classified  into  categories  in  the  
supportive  clinical  validity  range,  i.e.,  no  conditions  had  Refuted,  Disputed,  or  No  reported  
evidence.  To  approximate  a  negative  control,  we  also  evaluated  nine  recessive  conditions  not  
routinely  screened  in  a  general  population,  but  sometimes  screened  in  select  higher-­risk  groups,  
such  as  Ashkenazi  Jewish.  In  contrast  to  the  commonly  screened  conditions,  the  nine  rare  
conditions  predominantly  showed  either  Moderate  or  Limited  evidence  (Table  1,  Supplementary  
Table  2);;  these  categories  are  still  considered  supportive  of  clinical  validity.      
  
Next,  we  examined  the  distribution  of  quantitative  genetic  and  experimental  scores  (Figure  1,  
panel  A  shows  close-­up  examples  of  the  208  shown  in  panel  B).  Along  with  the  replication  over  
time,  these  scores  were  used  to  determine  the  ClinGen  classification  of  each  gene-­disease  
relationship.  Most  gene-­disease  pairs  had  the  maximum  possible  genetic  score  of  12  (Figure  
1A,  pink).  Experimental  scores  were  more  uniformly  distributed  across  the  possible  range  (i.e.,  
the  green-­shaded  bars  in  Figure  1B  range  from  0.5  to  6);;  however,  this  may  be  partially  due  to  
downward  censorship  bias  in  the  experimental  data,  which  occurs  because  upon  reaching  the  
highest  classification  status  (Definitive),  a  curator  may  discontinue  the  experimental  literature  
search.  Finally,  as  a  check  of  concordance  across  curating  laboratories,  we  compared  total  
scores  for  the  21  conditions  that  were  jointly  curated.  Nineteen  of  the  21  conditions  were  
classified  concordantly  as  Definitive.  The  other  two  gene-­disease  pairs  (SLC35A3  -­  autism  
spectrum  disorder/epilepsy/arthrogryposis  and  TMEM216  -­  Joubert  syndrome  2/Meckel  
syndrome  type  2)  were  classified  discordantly,  with  Myriad  classifying  both  as  Moderate  and  
Baylor  classifying  both  as  Definitive  (notably,  both  were  in  the  Supportive  evidence  category).  

8  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
After  discussion  between  the  two  teams,  consensus  was  reached  on  Moderate  classifications  
for  both  (Supplementary  Table  1).      
  

Discussion  
An  ECS  has  clinical  validity  if  it  correctly  discovers  pathogenic  variants  in  the  panel’s  genes  that  
determine  carrier  status  for  the  screened  conditions.  Accordingly,  evidence  of  the  following  is  
required  to  demonstrate  clinical  validity:  (1)  the  ECS  accurately  identifies  variants  in  genes  of  
interest,  (2)  the  ECS  correctly  classifies  the  discovered  variants  as  pathogenic  or  not,  and  (3)  
pathogenic  variants  in  the  genes  of  interest  are  associated  with  carrier  status  of  the  panel’s  
conditions.  The  first  has  been  demonstrated  via  analytical  validation  of  a  large  ECS  panel  
(Hogan  et  al.,  2018),  where  sensitivity  and  specificity  were  both  >99%  for  SNVs  and  indels.  The  
second  was  demonstrated  by  the  comparison  of  variant  classification  concordance  between  a  
commercial  ECS  offering  and  the  consensus  in  ClinVar  (Kaseniit  et  al.,  2019);;  notably,  
classifications  were  99%  concordant,  with  fewer  than  1  in  500  of  those  tested  expected  to  carry  
a  variant  with  disputed  classification.  The  third  is  addressed  in  this  study,  which  used  a  widely  
accepted  and  standardized  framework  to  show  that  >97.5%  of  genes  screened  by  the  superset  
of  two  large  ECS  panels  are  definitively  associated  with  the  specified  condition.  Taken  together,  
these  three  lines  of  evidence  strongly  establish  the  clinical  validity  of  ECS.  
  
Several  important  considerations  are  prompted  by  our  study.  First,  many  criteria  should  be  
assessed  when  implementing  ECS,  and  having  clinical  validity  is  not  sufficient  reason  alone  to  
include  a  condition  on  an  ECS  panel  (Henneman  et  al.,  2016).  For  instance,  the  severity,  clinical  
utility,  and  prevalence  of  screened  conditions  are  all  important  factors  (Beauchamp  et  al.,  2018):  
mild  or  exceedingly  rare  conditions  may  not  warrant  inclusion,  even  if  gene-­disease  association  

9  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
is  clear.  Second,  although  the  208  genes  studied  here  were  almost  entirely  classified  as  having  
Definitive  clinical  validity  evidence,  such  supportive  classifications  may  not  generalize  to  
extremely  large  panels;;  thus,  it  is  incumbent  upon  ECS  laboratories  to  undertake  clinical  validity  
evaluations  when  designing  panels.  Third,  we  anticipate  that  larger  panels  that  screen  for  very  
rare  conditions  may  have  unestablished  clinical  validity;;  eight  of  nine  (89%)  rare  conditions  
analyzed  as  "negative  controls"  in  this  study  had  less  than  Definitive  gene-­disease  association,  
as  compared  to  only  2.5%  with  non-­Definitive  evidence  for  conditions  on  the  panels.  
  
A  number  of  different  multi-­gene  panel  tests  ,  including  those  assessing  hereditary  cancer  
syndrome  risk,  cardiac  and  thoracic  condition  diagnosis,  and  underlying  causes  of  hearing  loss,  
have  been  evaluated  by  application  of  the  ClinGen  clinical  validity  framework  (DiStefano  et  al.,  
2019;;  Ingles  et  al.,  2019;;  Lee  et  al.,  2019;;  Renard  et  al.,  2018;;  Seifert  et  al.,  2019).  The  ability  of  
the  ClinGen  framework  to  be  applied  in  an  evidence-­based  and  systematic  manner  in  many  
different  disease  areas  is  a  testament  to  its  strength  as  a  tool  for  clinical  validity  assessment  of  
monogenic  conditions.  Additionally,  its  decisive  scoring  mechanism  controls  for  potential  
subjectivity  among  curators  as  to  the  weight  of  different  types  of  evidence.  Indeed,  in  this  study,  
19/21  (90%)  of  classifications  were  concordant,  and  all  showed  supportive  evidence  for  a  gene-­
disease  association.    
  
As  new  evidence  emerges,  gene-­disease  association  classifications  may  change,  particularly  
for  those  with  lower  point  totals  at  initial  curation,  such  as  Limited,  No  Reported  Evidence,  or  
Contradictory  Evidence  categories.  In  this  study,  one  gene,  HYLS1  (associated  with  
hydrolethalus  syndrome),  was  classified  as  having  Limited  evidence,  the  lowest  of  the  
supportive  categories.  In  several  studies  applying  the  ClinGen  framework,  discussion  of  genes  
classified  as  Limited  have  noted  the  need  to  regularly  revisit  curations  so  that  new  evidence  can  
be  assessed  (Grant  et  al.,  2018;;  McGlaughon  et  al.,  2019;;  Renard  et  al.,  2018).  McGlaughon  et  
10  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
al.  (2018)  retrospectively  analyzed  classifications  of  22  gene-­disease  pairs  curated  yearly,  and  
found  that  gene-­disease  associations  at  the  low  end  of  the  Limited  point  range  (<  2  points)  are  
more  likely  to  remain  Limited  or  become  Disputed/Refuted  than  than  those  initially  scored  in  mid  
to  upper  Limited  point  range  (2–6  points)  (McGlaughon  et  al.,  2018).  Notably,  HYLS1  was  
scored  at  5.5  points,  suggesting  that  it  will  remain  in  the  supportive  clinical  validity  category.  
Nonetheless,  it,  like  other  genes  being  screened  by  ECS,  should  be  subject  to  reassessment  as  
new  evidence  emerges.  
  
Limitations  to  this  study  should  be  noted.  First,  though  the  ClinGen  framework  should  result  in  
the  same  classification  even  when  applied  by  different  curators,  we  cannot  guarantee  that  other  
curators  would  have  categorized  the  conditions  identically  to  this  study.  Second,  and  related  to  
the  first,  one  curation  team  independently  categorized  more  conditions  than  the  other;;  if  a  bias  
toward  stronger  or  weaker  classifications  existed  in  the  team  that  completed  more  curations,  it  
may  have  skewed  the  results.  However,  we  checked  the  consistency  of  curations  between  the  
two  teams  by  curating  an  overlapping  set  of  21  conditions,  and  found  >90%  initial  concordance  
(and  eventual  consensus  on  the  remainder).  And  third,  the  categorizations  represent  the  state  of  
the  evidence  at  the  time  that  the  curations  were  completed.  As  noted  previously,  additional  
evidence  may  emerge  over  time,  changing  the  classification;;  however,  due  to  the  already  
rigorous  evidence  requirements  for  supportive  classifications,  additional  evidence  is  likely  to  
increase  the  strength  of  the  association,  rather  than  weaken  it  (McGlaughon  et  al.,  2018).    
  
Our  study  showed  that  the  vast  majority  of  conditions  on  the  ECS  panels  explored  herein  have  
definitive  support  for  gene-­disease  association,  a  critical  component  of  ECS  clinical  validity.  
Established  clinical  validity  is  necessary  to  provide  clinicians  with  the  confidence  that  test  results  
are  accurate  indicators  of  disease  causation.  This  is  especially  important  in  the  carrier  screening  
setting,  in  which  results  guide  reproductive  and  pregnancy  management  decisions.      
11  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  

Acknowledgements  
The  authors  thank  Jim  Goldberg  for  critical  review  of  the  manuscript  and  Anna  Gardiner  for  
assistance  in  manuscript  preparation.  

Consortia  
Myriad  Genetics  Curation  Team  
David  Tran,  Jessica  Conner,  Megan  Li,  Martha  Arnaud,  Lynne  Nazareth,  Kerri  Hensley,  Michael  
Hunter,  Sam  Cox,  Domenic  Previte,  Brianna  Campbell,  Katrina  Tanaka,  Candy  Heyen,  Kaitlin  
Sesock,  Srikanth  Appikonda,  Ildiko  Thibodeau,  Majesta  O'Bleness,  Matthew  Brown,  Caiqian  
Cropper,  Brandee  Price,  Juliette  Kahle,  Kamalika  Moulick,  Jessica  Ray,  John  Castiblanco,  Lea  
Gemmel,  Lisa  Spock,  Megan  Judkins  
  
Baylor  Genetics  Curation  Team  
Blake  Atwood,  Shen  Gu,  Ye  Cao,  Rajarshi  Ghosh,  Bo  Yuan,  Fan  Xia  

Conflict  of  Interest  
Conflict  of  interest  statement:  All  authors  are  current  or  former  employees  of  Myriad  Genetics  or  
Baylor  Genetics.  
  

Data  Availability  Statement  
All  curations  have  been  submitted  to  ClinGen  for  public  availability.  All  data  are  additionally  
available  from  the  corresponding  author  upon  request.  

  

  
12  

  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  

References  
Beauchamp,  K.  A.,  Muzzey,  D.,  Wong,  K.  K.,  Hogan,  G.  J.,  Karimi,  K.,  Candille,  S.  I.,  .  .  .  Haque,  
I.  S.  (2018).  Systematic  design  and  comparison  of  expanded  carrier  screening  panels.  
Genet  Med,  20(1),  55-­63.  doi:10.1038/gim.2017.69  
  
Ben-­Shachar,  R.,  Svenson,  A.,  Goldberg,  J.  D.,  &  Muzzey,  D.  (2019).  A  data-­driven  evaluation  
of  the  size  and  content  of  expanded  carrier  screening  panels.  Genet  Med,  21(9),  1931-­
1939.  doi:10.1038/s41436-­019-­0466-­5  
  
Chambers,  J.  D.,  Saret,  C.  J.,  Anderson,  J.  E.,  Deverka,  P.  A.,  Douglas,  M.  P.,  &  Phillips,  K.  A.  
(2017).  Examining  Evidence  in  U.S.  Payer  Coverage  Policies  for  Multi-­Gene  Panels  and  
Sequencing  Tests.  Int  J  Technol  Assess  Health  Care,  33(4),  534-­540.  
doi:10.1017/S0266462317000903  
  
DiStefano,  M.  T.,  Hemphill,  S.  E.,  Oza,  A.  M.,  Siegert,  R.  K.,  Grant,  A.  R.,  Hughes,  M.  Y.,  .  .  .  
ClinGen  Hearing  Loss  Clinical  Domain  Working,  G.  (2019).  ClinGen  expert  clinical  
validity  curation  of  164  hearing  loss  gene-­disease  pairs.  Genet  Med.  
doi:10.1038/s41436-­019-­0487-­0  
  
Grant,  A.  R.,  Cushman,  B.  J.,  Cave,  H.,  Dillon,  M.  W.,  Gelb,  B.  D.,  Gripp,  K.  W.,  .  .  .  Zenker,  M.  
(2018).  Assessing  the  gene-­disease  association  of  19  genes  with  the  RASopathies  using  
the  ClinGen  gene  curation  framework.  Hum  Mutat,  39(11),  1485-­1493.  
doi:10.1002/humu.23624  
  
Grody,  W.  W.,  Thompson,  B.  H.,  Gregg,  A.  R.,  Bean,  L.  H.,  Monaghan,  K.  G.,  Schneider,  A.,  &  
Lebo,  R.  V.  (2013).  ACMG  position  statement  on  prenatal/preconception  expanded  
carrier  screening.  Genet  Med,  15(6),  482-­483.  doi:10.1038/gim.2013.47  
  
Henneman,  L.,  Borry,  P.,  Chokoshvili,  D.,  Cornel,  M.  C.,  van  El,  C.  G.,  Forzano,  F.,  .  .  .  Peterlin,  
B.  (2016).  Responsible  implementation  of  expanded  carrier  screening.  Eur  J  Hum  
Genet,  24(6),  e1-­e12.  doi:10.1038/ejhg.2015.271  
  
Hogan,  G.  J.,  Vysotskaia,  V.  S.,  Beauchamp,  K.  A.,  Seisenberger,  S.,  Grauman,  P.  V.,  Haas,  K.  
R.,  .  .  .  Muzzey,  D.  (2018).  Validation  of  an  Expanded  Carrier  Screen  that  Optimizes  
Sensitivity  via  Full-­Exon  Sequencing  and  Panel-­wide  Copy  Number  Variant  
Identification.  Clin  Chem,  64(7),  1063-­1073.  doi:10.1373/clinchem.2018.286823  
  
Hosseini,  S.  M.,  Kim,  R.,  Udupa,  S.,  Costain,  G.,  Jobling,  R.,  Liston,  E.,  .  .  .  National  Institutes  of  
Health  Clinical  Genome  Resource,  C.  (2018).  Reappraisal  of  Reported  Genes  for  
Sudden  Arrhythmic  Death.  Circulation,  138(12),  1195-­1205.  
doi:10.1161/CIRCULATIONAHA.118.035070  
  
Ingles,  J.,  Goldstein,  J.,  Thaxton,  C.,  Caleshu,  C.,  Corty,  E.  W.,  Crowley,  S.  B.,  .  .  .  Funke,  B.  
(2019).  Evaluating  the  Clinical  Validity  of  Hypertrophic  Cardiomyopathy  Genes.  Circ  
Genom  Precis  Med,  12(2),  e002460.  doi:10.1161/CIRCGEN.119.002460  
  

13  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
Kaseniit,  K.  E.,  Collins,  E.,  Lo,  C.,  Moyer,  K.,  Mar-­Heyming,  R.,  Kang,  H.  P.,  &  Muzzey,  D.  
(2019).  Inter-­lab  concordance  of  variant  classifications  establishes  clinical  validity  of  
expanded  carrier  screening.  Clin  Genet,  96(3),  236-­245.  doi:10.1111/cge.13582  
  
Lee,  K.,  Seifert,  B.  A.,  Shimelis,  H.,  Ghosh,  R.,  Crowley,  S.  B.,  Carter,  N.  J.,  .  .  .  Couch,  F.  J.  
(2019).  Clinical  validity  assessment  of  genes  frequently  tested  on  hereditary  breast  and  
ovarian  cancer  susceptibility  sequencing  panels.  Genet  Med,  21(7),  1497-­1506.  
doi:10.1038/s41436-­018-­0361-­5  
  
McGlaughon,  J.  L.,  Goldstein,  J.  L.,  Thaxton,  C.,  Hemphill,  S.  E.,  &  Berg,  J.  S.  (2018).  The  
progression  of  the  ClinGen  gene  clinical  validity  classification  over  time.  Hum  Mutat,  
39(11),  1494-­1504.  doi:10.1002/humu.23604  
  
McGlaughon,  J.  L.,  Pasquali,  M.,  Wallace,  K.,  Ross,  J.,  Senol-­Cosar,  O.,  Shen,  W.,  .  .  .  Baudet,  
H.  G.  (2019).  Assessing  the  strength  of  evidence  for  genes  implicated  in  fatty  acid  
oxidation  disorders  using  the  ClinGen  clinical  validity  framework.  Mol  Genet  Metab.  
doi:10.1016/j.ymgme.2019.07.008  
  
National  Academies  of  Sciences  Engineering  and  Medicine.  (2017).  An  Evidence  Framework  for  
Genetic  Testing.  Washington  (DC).  Available  at  
https://www.ncbi.nlm.nih.gov/pubmed/28418631.  
  
Rehm,  H.  L.,  Berg,  J.  S.,  Brooks,  L.  D.,  Bustamante,  C.  D.,  Evans,  J.  P.,  Landrum,  M.  J.,  .  .  .  
ClinGen.  (2015).  ClinGen-­-­the  Clinical  Genome  Resource.  N  Engl  J  Med,  372(23),  2235-­
2242.  doi:10.1056/NEJMsr1406261  
  
Renard,  M.,  Francis,  C.,  Ghosh,  R.,  Scott,  A.  F.,  Witmer,  P.  D.,  Ades,  L.  C.,  .  .  .  De  Backer,  J.  
(2018).  Clinical  Validity  of  Genes  for  Heritable  Thoracic  Aortic  Aneurysm  and  Dissection.  
J  Am  Coll  Cardiol,  72(6),  605-­615.  doi:10.1016/j.jacc.2018.04.089  
  
Seifert,  B.  A.,  McGlaughon,  J.  L.,  Jackson,  S.  A.,  Ritter,  D.  I.,  Roberts,  M.  E.,  Schmidt,  R.  J.,  .  .  .  
Ferber,  M.  J.  (2019).  Determining  the  clinical  validity  of  hereditary  colorectal  cancer  and  
polyposis  susceptibility  genes  using  the  Clinical  Genome  Resource  Clinical  Validity  
Framework.  Genet  Med,  21(7),  1507-­1516.  doi:10.1038/s41436-­018-­0373-­1  
  
Strande,  N.  T.,  Riggs,  E.  R.,  Buchanan,  A.  H.,  Ceyhan-­Birsoy,  O.,  DiStefano,  M.,  Dwight,  S.  S.,  .  
.  .  Berg,  J.  S.  (2017).  Evaluating  the  Clinical  Validity  of  Gene-­Disease  Associations:  An  
Evidence-­Based  Framework  Developed  by  the  Clinical  Genome  Resource.  Am  J  Hum  
Genet,  100(6),  895-­906.  doi:10.1016/j.ajhg.2017.04.015  
  
The  Clinical  Genome  Resource.  Gene  Validity  Curations.  Retrieved  from  
https://www.clinicalgenome.org/site/assets/files/2169/gene_curation_sop_2016_version_
5_11_6_17.pdf  
  
The  Clinical  Genome  Resource  Gene  Curation  Working  Group.  (2017).  Gene  Clinical  Validity  
Curation  Process  Standard  Operating  Procedure,  Version  5.  Retrieved  from  
https://www.clinicalgenome.org/site/assets/files/2169/gene_curation_sop_2016_version_
5_11_6_17.pdf  
  
  
14  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
Table  1.    Gene-­disease  association  strengths  for  the  208  routine  ECS  conditions  and  the  nine  
that  approximated  “negative  controls.”      
  
  

  

Moderate   Limited  

Strong  

Carrier  
Screen  
Panel  
Gene  Set  

203  

0  

4  

1  

0  

0  

0  

208  

“Negative  
Control”  
Gene  Set  

1  

2  

4  

2  

0  

0  

0  

9  

  

15  
  

No  
Disputed   Refuted  
Evidence  

Definitive  

Total  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

  
Figure    1.    Application  of  ClinGen  framework  to  expanded  carrier  screening  conditions  
shows  predominantly  definitive  gene-­disease  associations.  (A)  The  evidence  underlying  
four  representative  gene-­disease  pairs  are  shown,  where  each  segment  of  the  bar  graph  
indicates  the  type  of  evidence  (color,  see  key)  and  score  (width  of  the  segment).    Classifications  
are  indicated  by  the  gray-­shaded  regions.  (B)  Bar  graphs  as  in  (A)  are  shown  for  the  193  gene-­
disease  pairs  classified  by  Myriad  and/or  Baylor.    (For  the  21  gene-­disease  pairs  classified  by  
both,  only  the  Myriad  data  is  shown  for  visual  clarity.)  
  

30  
  

medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014894; this version posted December 15, 2019. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Figure 1

It is made available under a CC-BY-NC-ND 4.0 International license .

